Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

NCT05823623 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Inetetamab
DRUG: Pyrotinib
DRUG: Oral Vinorelbine Tartrate

Sponsor

The First Affiliated Hospital with Nanjing Medical University